• Home
  • About Us
  • Science
    • Active Immunotherapies
    • Antibodies
  • Our Pipeline
  • News
  • Investors
    • Share Info
    • Financial Info
    • Documents & Presentations
    • Corporate Governance
  • Publications
  • Contact Us
    • Find a trial
    • Become an Investigator

Latest News

Featured News

Scancell reports Phase 2 data showing strongly improved outcomes in Late-Stage Melanoma with its Immunobody® iSCIB1+

Jul 22, 2025

Select the category

  • All categories
  • Covid-19
  • GlyMab
  • Immunobody
  • Interviews
  • iSCIB1+
  • Latest News
  • Media Coverage
  • Modi-1
  • Modi-2
  • Moditope
  • News
  • Presentations
  • Regulatory News
  • SCIB1

Select the year

  • All years
  • 2022
  • 2023
  • 2024
  • 2025
Clear Filters
U

Directorate Change and Appointment of Head of Development

February 5, 2024

Interim Results for the six months ended 31 October 2023

January 30, 2024

Notice of Interim Results and Presentation

January 26, 2024

MHRA approval to add a third cohort using iSCIB1+ to the SCOPE trial

January 17, 2024

Result of 2023 Annual General Meeting

November 30, 2023

Update on SCOPE trial

November 28, 2023
  • 4
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • 11
  • 12
  • 13
  • 14
  • 15
  • 16
  • 5
No results found.

Regulatory News Archive

View archive

JOIN OUR MAILING LIST

Sign up for news updates to stay up to date with Scancell.

    Scancell is focused on developing novel immunotherapies for the treatment of cancer and was founded in 1996 based on research led by Professor Lindy Durrant at the University of Nottingham in the UK.

    • Follow
    • Follow

    About Us
    Leadership Team
    Science
    Our Pipeline
    News
    Contact Us
    Find a Trial
    Become an Investigator

    ACTIVE IMMUNOTHERAPY

    ImmunoBody®
    Moditope®

    ANTIBODIES

    GlyMab®
    AvidiMab®

    Investors
    Company Profile
    Advisors
    Corporate Governance
    Documents & Presentations
    Share Information
    Financial Information

    Copyright © 2025 Scancell | Website Designed & Developed by Identity Creative | Privacy & Cookie Policy